Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Measuring inhibition of HIV replication by ex vivo CD8⁺ T cells.

Slichter CK, Friedrich DP, Smith RJ, Walsh PN, Mize G, Czartoski JL, McElrath MJ, Frahm N.

J Immunol Methods. 2014 Feb;404:71-80. doi: 10.1016/j.jim.2013.12.006. Epub 2013 Dec 25.

2.

Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials.

Walsh PN, Friedrich DP, Williams JA, Smith RJ, Stewart TL, Carter DK, Liao HX, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network.

J Immunol Methods. 2013 Aug 30;394(1-2):84-93. doi: 10.1016/j.jim.2013.05.007. Epub 2013 May 23.

3.

P1 and P2' site mutations convert protease nexin-2 from a factor XIa inhibitor to a plasmin inhibitor.

Navaneetham D, Wu W, Li H, Sinha D, Tuma RF, Walsh PN.

J Biochem. 2013 Feb;153(2):221-31. doi: 10.1093/jb/mvs133. Epub 2012 Nov 20.

4.

The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis.

Wu W, Li H, Navaneetham D, Reichenbach ZW, Tuma RF, Walsh PN.

Blood. 2012 Jul 19;120(3):671-7. doi: 10.1182/blood-2012-03-419523. Epub 2012 Jun 6.

5.

Productive recognition of factor IX by factor XIa exosites requires disulfide linkage between heavy and light chains of factor XIa.

Marcinkiewicz MM, Sinha D, Walsh PN.

J Biol Chem. 2012 Feb 24;287(9):6187-95. doi: 10.1074/jbc.M111.291989. Epub 2011 Dec 29.

6.

The role of factor XIa (FXIa) catalytic domain exosite residues in substrate catalysis and inhibition by the Kunitz protease inhibitor domain of protease nexin 2.

Su YC, Miller TN, Navaneetham D, Schoonmaker RT, Sinha D, Walsh PN.

J Biol Chem. 2011 Sep 9;286(36):31904-14. doi: 10.1074/jbc.M111.257527. Epub 2011 Jul 21.

7.

Ageing and health status in adults with intellectual disabilities: results of the European POMONA II study.

Haveman M, Perry J, Salvador-Carulla L, Walsh PN, Kerr M, Van Schrojenstein Lantman-de Valk H, Van Hove G, Berger DM, Azema B, Buono S, Cara AC, Germanavicius A, Linehan C, Määttä T, Tossebro J, Weber G.

J Intellect Dev Disabil. 2011 Mar;36(1):49-60. doi: 10.3109/13668250.2010.549464.

PMID:
21314593
8.

Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin.

Salameh MA, Soares AS, Navaneetham D, Sinha D, Walsh PN, Radisky ES.

J Biol Chem. 2010 Nov 19;285(47):36884-96. doi: 10.1074/jbc.M110.171348. Epub 2010 Sep 22.

9.

Mechanisms and specificity of factor XIa and trypsin inhibition by protease nexin 2 and basic pancreatic trypsin inhibitor.

Navaneetham D, Sinha D, Walsh PN.

J Biochem. 2010 Oct;148(4):467-79. doi: 10.1093/jb/mvq080. Epub 2010 Jul 20.

10.

Characteristics, supports, and quality of life of Irish adults with intellectual disability in life-sharing residential communities.

Fahey A, Walsh PN, Emerson E, Guerin S.

J Intellect Dev Disabil. 2010 Jun;35(2):66-76. doi: 10.3109/13668251003724635.

PMID:
20560694
11.

Sampling and ethical issues in a multicenter study on health of people with intellectual disabilities.

Veenstra MY, Walsh PN, van Schrojenstein Lantman-de Valk HM, Haveman MJ, Linehan C, Kerr MP, Weber G, Salvador-Carulla L, Carmen-Cara A, Azema B, Buono S, Germanavicius A, Tossebro J, Maatta T, van Hove G, Moravec D.

J Clin Epidemiol. 2010 Oct;63(10):1091-100. doi: 10.1016/j.jclinepi.2009.12.001. Epub 2010 Mar 20.

PMID:
20304607
12.

Platelets: yin and yang.

Walsh PN.

Blood. 2010 Jan 7;115(1):1-2. doi: 10.1182/blood-2009-10-251272. No abstract available.

13.

Examining the prevalence of epilepsy and delivery of epilepsy care in Ireland.

Linehan C, Kerr MP, Walsh PN, Brady G, Kelleher C, Delanty N, Dawson F, Glynn M.

Epilepsia. 2010 May;51(5):845-52. doi: 10.1111/j.1528-1167.2009.02417.x. Epub 2009 Dec 1.

14.

The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin.

Salameh MA, Robinson JL, Navaneetham D, Sinha D, Madden BJ, Walsh PN, Radisky ES.

J Biol Chem. 2010 Jan 15;285(3):1939-49. doi: 10.1074/jbc.M109.057216. Epub 2009 Nov 17.

15.

Factor XI contributes to thrombin generation in the absence of factor XII.

Kravtsov DV, Matafonov A, Tucker EI, Sun MF, Walsh PN, Gruber A, Gailani D.

Blood. 2009 Jul 9;114(2):452-8. doi: 10.1182/blood-2009-02-203604. Epub 2009 Apr 7.

16.

Managing health problems in people with intellectual disabilities.

van Schrojenstein Lantman-de Valk HM, Walsh PN.

BMJ. 2008 Dec 8;337:a2507. doi: 10.1136/bmj.a2507. Review. No abstract available.

PMID:
19064601
17.

Health indicators and intellectual disability.

Walsh PN.

Curr Opin Psychiatry. 2008 Sep;21(5):474-8. doi: 10.1097/YCO.0b013e3283065bc6. Review.

PMID:
18650690
18.

Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa.

Wu W, Sinha D, Shikov S, Yip CK, Walz T, Billings PC, Lear JD, Walsh PN.

J Biol Chem. 2008 Jul 4;283(27):18655-64. doi: 10.1074/jbc.M802275200. Epub 2008 Apr 25.

19.

Defective binding of factor XI-N248 to activated human platelets.

Sun MF, Ho D, Martincic D, Ware RE, Walsh PN, Gailani D.

Blood. 2007 Dec 15;110(13):4164. No abstract available.

20.

A catalytic domain exosite (Cys527-Cys542) in factor XIa mediates binding to a site on activated platelets.

Miller TN, Sinha D, Baird TR, Walsh PN.

Biochemistry. 2007 Dec 18;46(50):14450-60. Epub 2007 Nov 17.

21.

Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor-XI activation by thrombin.

Walsh PN.

Biochemistry. 2007 Nov 6;46(44):12886-7. Epub 2007 Oct 11. No abstract available.

PMID:
17929839
22.

Solution structure of the A4 domain of factor XI sheds light on the mechanism of zymogen activation.

Samuel D, Cheng H, Riley PW, Canutescu AA, Nagaswami C, Weisel JW, Bu Z, Walsh PN, Roder H.

Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15693-8. Epub 2007 Sep 20.

23.
24.
25.

Variations in the social inclusion of people with intellectual disabilities in supported living schemes and residential settings.

McConkey R, Abbott S, Walsh PN, Linehan C, Emerson E.

J Intellect Disabil Res. 2007 Mar;51(Pt 3):207-17. Erratum in: J Intellect Disabil Res. 2007 Apr;51(Pt 4):327. Abbott, S [added]; Walsh, P N [added]; Linehan, Christine [added]; Emerson, Eric [added].

PMID:
17300416
26.

Dimer dissociation and unfolding mechanism of coagulation factor XI apple 4 domain: spectroscopic and mutational analysis.

Riley PW, Cheng H, Samuel D, Roder H, Walsh PN.

J Mol Biol. 2007 Mar 23;367(2):558-73. Epub 2006 Dec 29.

27.
28.

Crystal structure of the factor XI zymogen reveals a pathway for transactivation.

Papagrigoriou E, McEwan PA, Walsh PN, Emsley J.

Nat Struct Mol Biol. 2006 Jun;13(6):557-8. Epub 2006 May 14.

PMID:
16699514
29.

Ageing and health issues in intellectual disabilities.

Walsh PN.

Curr Opin Psychiatry. 2005 Sep;18(5):502-6.

PMID:
16639108
30.
31.

The relationship between quality of life and self-determination: an international study.

Lachapelle Y, Wehmeyer ML, Haelewyck MC, Courbois Y, Keith KD, Schalock R, Verdugo MA, Walsh PN.

J Intellect Disabil Res. 2005 Oct;49(Pt 10):740-4.

PMID:
16162119
32.

Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2.

Navaneetham D, Jin L, Pandey P, Strickler JE, Babine RE, Abdel-Meguid SS, Walsh PN.

J Biol Chem. 2005 Oct 28;280(43):36165-75. Epub 2005 Aug 6.

33.

Factor XIa dimer in the activation of factor IX.

Sinha D, Marcinkiewicz M, Lear JD, Walsh PN.

Biochemistry. 2005 Aug 2;44(30):10416-22.

PMID:
16042419
34.

A Glu113Ala mutation within a factor VIII Ca2+-binding site enhances cofactor interactions in factor Xase.

Wakabayashi H, Su YC, Ahmad SS, Walsh PN, Fay PJ.

Biochemistry. 2005 Aug 2;44(30):10298-304.

36.

Do platelets synthesize factor XI?

Gailani D, Zivelin A, Sinha D, Walsh PN.

J Thromb Haemost. 2004 Oct;2(10):1709-12. Review. No abstract available.

37.

Factor XI interacts with the leucine-rich repeats of glycoprotein Ibalpha on the activated platelet.

Baglia FA, Shrimpton CN, Emsley J, Kitagawa K, Ruggeri ZM, López JA, Walsh PN.

J Biol Chem. 2004 Nov 19;279(47):49323-9. Epub 2004 Sep 16.

38.

Platelet coagulation-protein interactions.

Walsh PN.

Semin Thromb Hemost. 2004 Aug;30(4):461-71. Review.

PMID:
15354267
40.

Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI.

Baglia FA, Gailani D, López JA, Walsh PN.

J Biol Chem. 2004 Oct 29;279(44):45470-6. Epub 2004 Aug 17.

41.

Retreat and resilience: life experiences of older women with intellectual disabilities.

LeRoy BW, Walsh PN, Kulik N, Rooney M.

Am J Ment Retard. 2004 Sep;109(5):429-41.

PMID:
15298519
42.

Allosteric modification of factor XIa functional activity upon binding to polyanions.

Sinha D, Badellino KO, Marcinkiewicz M, Walsh PN.

Biochemistry. 2004 Jun 15;43(23):7593-600.

PMID:
15182201
43.

A subpopulation of platelets responds to thrombin- or SFLLRN-stimulation with binding sites for factor IXa.

London FS, Marcinkiewicz M, Walsh PN.

J Biol Chem. 2004 May 7;279(19):19854-9. Epub 2004 Mar 9.

44.

The Resident Choice Scale: a measure to assess opportunities for self-determination in residential settings.

Hatton C, Emerson E, Robertson J, Gregory N, Kessissoglou S, Walsh PN.

J Intellect Disabil Res. 2004 Feb;48(Pt 2):103-13.

PMID:
14723653
46.

Health indicators for people with intellectual disabilities: a European perspective.

Walsh PN, Kerr M, van Schrojenstein Lantman-de Valk HM.

Eur J Public Health. 2003 Sep;13(3 Suppl):47-50.

PMID:
14533748
47.

Roles of factor XI, platelets and tissue factor-initiated blood coagulation.

Walsh PN.

J Thromb Haemost. 2003 Oct;1(10):2081-6. No abstract available.

48.
49.

The assembly of the factor X-activating complex on activated human platelets.

Ahmad SS, London FS, Walsh PN.

J Thromb Haemost. 2003 Jan;1(1):48-59. Review.

50.

Supplemental Content

Loading ...
Support Center